18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

      , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      The Lancet Oncology
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Journal
          The Lancet Oncology
          The Lancet Oncology
          Elsevier BV
          14702045
          July 2019
          July 2019
          Article
          10.1016/S1470-2045(19)30326-2
          31296491
          849c63d0-542e-4a6e-8030-42f1f6b8ece0
          © 2019

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article